Compare ASRV & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ASRV | PMVP |
|---|---|---|
| Founded | 1983 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.9M | 76.8M |
| IPO Year | 1994 | 2020 |
| Metric | ASRV | PMVP |
|---|---|---|
| Price | $3.70 | $1.21 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 10.6K | ★ 380.1K |
| Earning Date | 04-21-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.16% | N/A |
| EPS Growth | ★ 61.90 | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $14,634,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $34.54 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.64 | $0.85 |
| 52 Week High | $4.04 | $1.88 |
| Indicator | ASRV | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 42.32 | 33.96 |
| Support Level | $3.62 | $1.09 |
| Resistance Level | $3.96 | $1.26 |
| Average True Range (ATR) | 0.13 | 0.08 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 28.95 | 4.29 |
AmeriServ Financial Inc is a bank holding company. The company and its subsidiaries derive substantially all of their income from banking, bank-related services, and trust-related services. Its operating segment includes community banking and it generates maximum revenue. The community banking segment includes both retail and commercial banking activities. The company also offers retail banking which includes the deposit-gathering branch franchise and lending to both individuals and small businesses; Lending activities include residential mortgage loans, direct consumer loans, and small business commercial loans; Commercial banking to businesses includes commercial loans, business services, and CRE loans.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.